Edesa Biotech partners with Kyorin to develop, commercialize paridiprubart in Japan
EDSA•Edesa Biotech signed an exclusive licensing agreement with Kyorin to develop and commercialize paridiprubart in Japan for acute respiratory distress syndrome. Edesa will receive $12 million upfront, with up to approximately $134 million in potential milestones and tiered double-digit royalties.
1. Japan licensing agreement
Kyorin will fund development, regulatory and commercialization activities in Japan. Edesa retains rights outside Japan and will manufacture and supply the product to Kyorin.
